Miscellaneous
In another news episode, hear a 5-minute summary of the VERTIS CV post hoc analysis presented at ESC 2021. VERTIS CV was the the cardiovascular outcomes trial investigating the SGLT2 inhibitor ertugliflozin in people with type 2 diabetes and cardiovascular disease; this latest analysis looked at whether the effects of ertugliflozin on cardiovascular and renal outcomes varied according to baseline metformin use. Listen for a quick overview of the key findings. Abstract: Cosentino F, et al. Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial. Eur Heart J 2021. In press For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. Funding statement: This independent educational activity is supported by educational grants from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.